person · Reporting owner
GROENHUYSEN WILHELMUS CM
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | June 28, 2024 | August 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 28, 2024 · Filed August 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 252,290 |
Reported balance
After 2024-06-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 1,055 · Balance 252,290 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 2,133 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.10 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.75 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.00 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.50 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 1,925 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 4,800 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · derivative · entry 14 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,832 Underlying: Ordinary Shares · 4,800 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,900 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · derivative · entry 13 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,169 Underlying: Ordinary Shares · 1,900 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,900 | $80.14 | $152,267.90 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F1 · price: On November 11, 2019, Mr. Groenhuysen sold 1,900 shares in multiple trades at prices ranging from $80.00 to $80.38. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,900 | $7.03 | $13,357.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,800 | $80.12 | $384,571.20 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F2 · price: On November 11, 2019, Mr. Groenhuysen sold 4,800 shares in multiple trades at prices ranging from $80.00 to $80.27. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 4,800 | $3.44 | $16,512.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,900 | $80.15 | $152,275.50 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F1 · price: On November 11, 2019, Mr. Groenhuysen sold 1,900 shares in multiple trades at prices ranging from $80.00 to $80.38. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,900 | $3.44 | $6,536.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,961 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · derivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,286 Underlying: Ordinary Shares · 1,961 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 4,031 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · derivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,632 Underlying: Ordinary Shares · 4,031 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · derivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,069 Underlying: Ordinary Shares · 2,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $81.19 | $24,357.90 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F7 · shares: On September 24, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 300 shares in multiple trades at prices ranging from $81.17 - $81.21. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,661 | $80.56 | $133,803.52 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,479 F6 · shares: On September 24, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,661 shares in multiple trades at prices ranging from $80.07 - $80.90. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,961 | $7.03 | $13,785.83 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 700 | $81.18 | $56,823.90 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F5 · shares: On September 24, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 700 shares in multiple trades at prices ranging from $81.13 - $81.21. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,331 | $80.50 | $268,155.49 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,879 F4 · shares: On September 24, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,331 shares in multiple trades at prices ranging from $80.01 - $80.90. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 4,031 | $3.44 | $13,866.64 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $81.19 | $24,357.90 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F3 · shares: On September 24, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 300 shares in multiple trades at prices ranging from $81.17 - $81.21. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,700 | $80.53 | $136,899.30 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,479 F2 · shares: On September 24, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,700 shares in multiple trades at prices ranging from $80.04 -$80.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 23:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,000 | $3.44 | $6,880.00 |
DisclosureSEC source: 0000899243-19-024311 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · derivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,663 Underlying: Ordinary Shares · 25,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,300 | $79.01 | $1,761,856.10 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F6 · price: On September 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 22,300 shares in multiple trades at prices ranging from $78.60 to $79.46. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,700 | $78.33 | $211,477.50 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,479 F5 · price: On September 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,700 shares in multiple trades at prices ranging from $77.54 to $78.54. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $3.44 | $86,000.00 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · derivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,663 Underlying: Ordinary Shares · 25,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $80.96 | $32,383.60 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F4 · price: On September 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 400 shares in multiple trades at prices ranging from $80.92 to $80.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,502 | $80.27 | $1,083,792.04 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,579 F3 · price: On September 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 13,502 shares in multiple trades at prices ranging from $79.89 to $80.87. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,098 | $79.24 | $879,372.23 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,081 F2 · price: On September 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 11,098 shares in multiple trades at prices ranging from $78.760 to $79.75. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $3.44 | $86,000.00 |
DisclosureSEC source: 0001209191-19-049855 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · derivative · entry 13 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,663 Underlying: Ordinary Shares · 25,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 201 | $81.05 | $16,291.05 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F10 · price: On September 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 201 shares in multiple trades at prices ranging from $81.02 to $81.08. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,107 | $80.51 | $813,694.36 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,380 F9 · price: On September 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 10,107 shares in multiple trades at prices ranging from $80.00 to $80.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,499 | $79.42 | $516,150.58 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,487 F8 · price: On September 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 6,499 shares in multiple trades at prices ranging from $79.00 to $79.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,193 | $78.50 | $643,142.31 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,986 F7 · price: On September 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 8,193 shares in multiple trades at prices ranging from $77.97 to $78.95. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $3.44 | $86,000.00 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · derivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,663 Underlying: Ordinary Shares · 25,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,061 | $79.19 | $321,598.71 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F6 · price: On September 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 4,061 shares in multiple trades at prices ranging from $79.06 to $79.46. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,015 | $78.72 | $867,056.74 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,240 F5 · price: On September 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 11,015 shares in multiple trades at prices ranging from $78.06 to $79.05. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,008 | $77.52 | $310,692.14 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,255 F4 · price: On September 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 4,008 shares in multiple trades at prices ranging from $77.03 to $78.00. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,974 | $76.37 | $303,478.48 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,263 F3 · price: On September 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,974 shares in multiple trades at prices ranging from $76.01 to $76.99. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,942 | $75.56 | $146,737.52 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,237 F2 · price: On September 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,942 shares in multiple trades at prices ranging from $75.00 to $76.00. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $3.44 | $86,000.00 |
DisclosureSEC source: 0001209191-19-049477 · doc4.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · derivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,663 Underlying: Ordinary Shares · 25,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,709 | $76.45 | $436,447.34 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F9 · price: On September 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 5,709 shares in multiple trades at prices ranging from $76.00 to $76.99. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 19,291 | $75.28 | $1,452,187.90 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,888 F8 · price: On September 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 19,291 shares in multiple trades at prices ranging from $75.00 to $75.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $3.44 | $86,000.00 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · derivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,663 Underlying: Ordinary Shares · 25,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 200 | $84.41 | $16,882.00 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F7 · price: On September 9, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $84.34 to $84.48. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,100 | $82.74 | $91,010.70 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,379 F6 · price: On September 9, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,100 shares in multiple trades at prices ranging from $82.60 to $83.14. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,800 | $82.05 | $886,129.20 |
DisclosureSEC source: 0001209191-19-049141 · doc4.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,479 F5 · price: On September 9, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 10,800 shares in multiple trades at prices ranging from $81.56 to $82.50. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.